Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as a novel treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.
Stock Performance
Relmada Therapeutics Inc. News 10 articles
- Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
- Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
- Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
- Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
- Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
- Psychedelic Stock Market Update July 2022
- Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
- Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
- Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial